<a name="Heading517"></a><strong>References</strong></h1>
<p>1. Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. <em>J Clin Oncol</em>. 2015;33:654-656. </p>
<p>2. Cohen&#160;AT.&#160;Discoveries in thrombosis care for medical patients.&#160;<em>Semin Thromb Hemost</em>. 2002;28(suppl 3):13-17.</p>

<p>3. ClinicalTrials.gov. Apixaban for the prevention of venous thromboembolism in cancer patients (AVERT). https://clinicaltrials.gov/ct2/show/NCT02048865. Accessed August 23, 2018.</p>

<p>4. Khorana AA, et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial. <em>Thromb Haemost</em>. 2017;117:2135-2145. </p>

<p>5. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. <em>N Engl J Med.</em> 2018;378:615-624.</p>

<p>6. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). <em>J Clin Oncol</em>. 2018;36:2017-2023. </p>

<p>7. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. <em>N Engl J Med</em>. 2003;349:146-153.</p>

<p>8. Khorana AA, McCrae KR, Milentijevic D, et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. <em>Res Pract Thromb Haemost</em>. 2017;1:14-22. </p>

<p>9. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. <em>Blood</em>. 2002;100:3484-3488. </p>

<p>10. Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer associated venous thromboembolism. <em>Circulation</em> 2012; 126: 448-454.</p>

<p>11. Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. <em>J Thromb Haemost</em>. 2018. [Epub ahead of print]</p>

<p>12. Clinicaltrials.gov. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO)  https://clinicaltrials.gov/ct2/show/NCT03045406. Accessed August 23, 2018.</p>